0LB2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Supernus Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 41.94 USD -2.17% Market Closed

Market Cap: $2.4B

	Supernus Pharmaceuticals Inc LSE:0LB2	US
B	Blue Lagoon Resources Inc CNSX:BLLG	CA
	Dave and Buster's Entertainment, Inc NASDAQ:PLAY	US
T	Tandem Diabetes Care Inc LSE:0M0F	US
B	Bank AL-Habib Ltd KAR:BAHL	PK
	Maruti Suzuki India Ltd BSE:532500	IN
V	VICI Properties Inc XMUN:1KN	US
	Kokuyo Co Ltd F:KOK	JP
C	CA Sales Holdings Ltd JSE:CAA	ZA
B	BAE Systems PLC XETRA:BSP	UK

Profitability Summary

Supernus Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

88%

Strong 3Y Average Gross Margin

89%

Gross Margin is Increasing

86% > 88%

Negative Operating Margin

Low 3Y Average Operating Margin

Declining Operating Margin

5% > 0%

Negative Net Margin

-13%

Low 3Y Average Net Margin

Declining Net Margin

4% > -13%

Healthy Free Cash Flow Margin

Strong 3Y Average Free Cash Flow Margin

18%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.